Accessible Hearing Aids is owned and operated by Dr. Joe “Tripp” Griffith, III.

It’s recommended that you have your hearing screened at least once a year, especially if you are over the age of 40. — Dr. Joe Griffith

NEW ORLEANS (PRWEB)
September 15, 2022

Accessible Hearings Aids (AHA), owned and operated by Dr. Joe “Tripp” Griffith III, continues to demonstrate their commitment to the latest digital hearing aid technology and to helping patients get the most out of their hearing aids. While serving the region from their Metairie office, they have reached a national audience through their YouTube channel that features several instructional videos on hearing aid cleaning and care. AHA also offers a free hearing evaluation that has assisted countless clients in obtaining free hearing aids if qualified through insurance or other support.

Dr. Griffith understands how crucial treatment of hearing loss is to a patient’s overall physical, mental, and emotional health. “Treatment of hearing loss has been shown to improve communication in relationships, sense of control over your life, social participation, and emotional stability,” Dr. Griffith said. The benefits of hearing aids increase the enjoyability of life’s moments and improve your engagement with people and your surroundings. Hearing aids enable you to contribute better to the workplace, increase your productivity, and allow room for greater improvements in personal and professional relationships.

Accessible Hearing Aid’s website has a free hearing test available for all ages to get patients started on their journey to better hearing. “It’s recommended that you have your hearing screened at least once a year, especially if you are over the age of 40,” Dr. Griffith said. AHA offers a free hearing evaluation that not only diagnoses problems and determines the best avenue for treatment but also guides patients trying to qualify for their hearing aids to be paid through private insurance, Medicare, Medicaid, vocational rehab, national and state foundations, and the Veterans Health Administration. AHA also guarantees the most up-to-date advances in hearing aid technology, such as programmable processors fine-tuned for each user, noise and wind reduction, wireless connectivity to phones and other mobile devices, and compatibility with doorbells and smoke alarms.

After your evaluation, if it’s shown you could benefit from hearing aids, AHA offers live speech mapping and real-ear measures during fitting that immediately show the patient how their hearing will improve. Real-ear measures tune amplification based on your personal needs. Custom earmolds ensure that patients who play music, hunt, swim, and frequently use Bluetooth to make phone calls have the best protection possible. AHA supplies batteries in small packets or bulk boxes, so your new hearing aids will always be charged and ready to go. Before the end of your fitting appointment, you will receive information on cleaning your new hearing aids, replacing batteries, filters, and domes, and how to program Bluetooth/FM compatible accessories with your hearing aids. Accessible Hearing Aid’s team is always available to reassess this information with you for as long as you use hearing aids. Most of this information is publicly available in the form of highly educational videos on AHA’s YouTube channel.

Dr. Joe Griffith began a private practice in audiology in 2015, intending to make hearing treatment easily available by offering house calls and in-house visits to patients’ offices or living communities. He received his Doctorate in Audiology from Auburn University and is affiliated with the American Speech-Language and Hearing Association and the Louisiana Academy of Audiology. Dr. Griffith sees and treats patients of all ages.

Improving your quality of life through better hearing is only a phone call away! Call Dr. Joe Griffith at 504-738-4557 to schedule your free hearing evaluation or visit https://accessiblehearingaids.com to fill out the Accessible Hearing Aid’s contact form.

Share article on social media or email:

It is important that we not only open up the conversation about infertility but provide education on how to be a supportive friend.

MCLEAN, Va. (PRWEB)
September 15, 2022

An estimated 1 in 8 couples experience infertility and many may be struggling silently. Studies have shown that those undergoing fertility can face a variety of emotional and psychological issues, such as reduced self-esteem, loneliness, feelings of failure, grief and depression. These emotions can be heightened at peak times such as during the holidays. To combat that, RESOLVE: The National Infertility Association and First Response™ have teamed up to launch Fertile Friends, an initiative highlighting available support and resources for those experiencing infertility as well as tips for friends and family on how they can support those trying to conceive.

“For those going through infertility, it can be incredibly stressful, especially during times when everyone is posting pictures of their children, like back to school and the holiday season,” said RESOLVE Board Member and Vice Chair Elizabeth Grill, Psy.D., clinical psychologist and medical researcher specializing in the emotional aspects of infertility. “Individuals dealing with infertility cope in different ways, and while friends and family might not always understand the way they are choosing to face this challenge, it’s important that they demonstrate their support. Whether attending doctor’s appointments, helping with injections, or simply asking what would be helpful, there are many ways to support a friend’s mental health and remind them that they aren’t alone.”

RESOLVE offers support groups, which provide a safe space to meet others facing similar struggles with infertility and family building. Additionally, RESOLVE and First Response™ are sharing the following tips on how to be mindful Fertile Friends during the upcoming holiday seasons.

• Let them know you care: Talk to those in your life who are struggling and let them know you are there to support them when they need it. Make sure they know that you aren’t gossiping about their struggles and have nothing but love and support for them. Make it clear that you will be there however they need you to be.
• Avoid giving unsolicited advice: Offering advice or solutions such as asking if they’ve considered IVF or adoption is not helpful (if they aren’t ready to explore those solutions yet). Alternative ways to become a parent such as these are long, painful processes and in no way casual conversation or easy fixes.
• Talk about other things: Talk to your childless friends about more than just your children. If you are pregnant, avoid complaining about your pregnancy. When it comes to pregnancy announcements, be cognizant of your friend’s feelings and struggles, and consider sharing the news with them in a private, personal way before the big announcement.
• Don’t minimize the problem: Joking that someone should enjoy their sleep schedule while they can or that they’re lucky they aren’t as stressed over the holidays without children can be damaging. Commenting about how life is easier, or even better, without children simply does not provide comfort.
• Understand their decisions: Acknowledge that you’re aware that these times can be particularly painful and challenging for some and that you won’t be offended by the decisions they may need to make in order to be happy. Don’t take it personally if your friend decides to leave a holiday party early or mute you on social media to avoid seeing an overload of family photos.

“Fertility treatments can take a toll on all aspects of a patient’s health and, unfortunately, their mental health is often ignored,” said Banafsheh Kashani, M.D., FACOG, double board-certified OB-GYN, reproductive endocrinology and infertility specialist. “Those dealing with infertility can go through many highs and lows during the process and their loved ones may not know how to best support them. It is important that we not only open up the conversation about infertility but provide education on how to be a supportive friend.”

The tips for friends and family as well as links to find a support group for those dealing with infertility can be found on RESOLVE’s website.

In April 2022, RESOLVE and First Response™ announced an initiative to increase awareness of the need for support among the infertility community and rebuild RESOLVE’s nationwide network of support groups, with the goal of establishing one new support group in each state by the end of 2022. Today, RESOLVE and First Response™ are continuing this partnership to expand support for the infertility community, providing advice and acknowledging the need for mindful Fertile Friends to those struggling to start or expand their families.

RESOLVE.org is home to many resources for the infertility community and those aiming to support it, including free support groups, books, podcasts, and other online resources, kitchen table conversations, and more. In April 2022, First Response™ launched The Pregnancy Hub by First Response™, an online community that aims to connect, inspire, and provide resources to those navigating trying to conceive (TTC), pregnancy and motherhood.

About RESOLVE: The National Infertility Association: Established in 1974, RESOLVE: The National Infertility Association is a non-profit organization with the only established nationwide network mandated to promote reproductive health and to ensure equal access to all family-building options for anyone experiencing infertility or challenges in building their family. One in eight U.S. couples of childbearing age has trouble conceiving or carrying a pregnancy to term. RESOLVE addresses this public health issue by providing community to all who need it, connecting them with others who can help, empowering them to find resolution and giving voice to their demands for access to all family-building options. For more information, visit http://www.RESOLVE.org.

About First Response™: For over 30 years, First Response™, the #1 Most Trusted(1) and #1 Pharmacist Recommended(2) pregnancy test brand, has been dedicated to being a source of truth and guidance by offering an array of products that deliver fast, accurate results when you need them most, including First Response™ Early Result Pregnancy Test that detects all forms of the pregnancy hormone commonly found in urine and can tell you six days sooner than your missed period(3). The Early Result test is also compatible with the new EasyRead app, allowing for twice the certainty of your result(4) by instantly converting your pregnancy test results into the words “Pregnant” or “Not Pregnant. The Pre-Seed™ Fertility Lubricant is designed to be isotonic and pH balanced, similar to that of the vaginal environment, to aid in supporting sperm survival. For more information, visit http://www.FirstResponse.com.

Share article on social media or email:

Their leadership and expertise support the continued growth we are seeing in healthcare development opportunities and further strengthen our ability to deliver quality medical office buildings, ambulatory care centers and other development projects for our healthcare provider clients.

MILWAUKEE (PRWEB)
September 15, 2022

Hammes is pleased to announce the hire of two seasoned healthcare development professionals, Steve Buckeridge and David Ransom. Steve Buckeridge joins the team as a Senior Vice President with Hammes Partners while David Ransom joins Hammes Healthcare as Vice President of National Development Services.

“We are thrilled to welcome experienced professionals of Steve and David’s caliber to Hammes,” said Todd Kibler, Managing Principal of Hammes Partners. “Their leadership and expertise support the continued growth we are seeing in healthcare development opportunities and further strengthen our ability to deliver quality medical office buildings, ambulatory care centers and other development projects for our healthcare provider clients.”

Steve brings more than 25 years of healthcare real estate planning, development, acquisitions and transactional experience. Prior to joining Hammes, Steve was a Development Principal for MedCraft Healthcare Real Estate. Before this, he served as Senior Vice President at Health Care REIT (now Welltower).

David brings more than 30 years of experience leading complex real estate development, design and construction projects, including work with several notable health systems. Prior to joining Hammes, David was a Senior Vice President of Development for MedCore Partners. He is a licensed architect and will be based out of Hammes’ Dallas office.

About Hammes

Founded in 1991, Hammes is a vertically integrated real estate solutions platform specializing in healthcare real estate strategy and planning, project management, development, investment, and property management. As a testament to our deep healthcare industry experience, Hammes has been recognized as one of the nation’s leading healthcare developers by Modern Healthcare’s Construction & Design Survey for 24 consecutive years—including 19 years as No. 1—and by Revista’s Outpatient Healthcare Real Estate Development Report. Headquartered in Milwaukee, Wisconsin, Hammes provides services through a network of regional offices strategically located across the United States. http://www.hammes.com

Share article on social media or email:

The MATISSE™ ACIF Cage System is available in numerous footprints, heights, lordotic angles and materials.

We’re honored by the TFDA’s approval and are excited to work with our Taiwan distributor partner to make this important spinal technology readily available throughout Taiwan.

DALLAS (PRWEB)
September 15, 2022

The Taiwan Food and Drug Administration (TFDA), a part of the Ministry of Health and Welfare, has granted CTL Amedica Corporation a license for the MATISSE™ Anterior Cervical Interbody Fusion (ACIF) Cage System. The official license, DHA 05603556709, enables CTL Amedica to market the MATISSE™ ACIF Cage System in Taiwan, a crucial medical device market, particularly for spinal technology.

“We’re honored by the TFDA’s approval and are excited to work with our Taiwan distributor partner to make this important spinal technology readily available throughout Taiwan,” said Daniel Chon, CEO of CTL Amedica. “We hope to have it commercially available throughout Taiwan in the coming months and eventually in markets throughout Asia.”

Named after the famous French impressionist painter Henri Matisse, the MATISSE™ ACIF Cage System is a work of art and of science, engineered to accommodate a wide range of patient anatomies and surgeon preferences. It features streamlined instrumentation and a tapered leading edge for easy insertion, as well as, a large graft area to further promote bone fusion.

The MATISSE™ ACIF Cage System is available in numerous footprints, heights, lordotic angles and materials, including Titanium, PEEK and Titanium-plated PEEK. Both Titanium and Titanium-plated PEEK feature CTL Amedica’s proprietary TiCro™ surface technology. TiCro™ surface technology significantly increases contact surface area and enhances bone interlocking properties.

CTL Amedica is a forward-thinking medical device design, development and manufacturing company. CTL Amedica maintains a Texas-based headquarters and in-house manufacturing facility, along with a Pennsylvania-based R&D Center of Excellence. A leader in the medical device technology and biomaterials space, CTL Amedica provides a full line of cervical, thoracic and lumbar fusion and fixation products. In addition, it is the world’s exclusive provider of silicon nitride spine products. Silicon nitride demonstrates an enhanced osteogenic response for enhanced fusion, promotes unique anti-bacterial properties and provides comprehensive imaging across all modalities. For more information, visit https://www.ctlamedica.com/.

Share article on social media or email:

International Congress of Parkinson’s Disease and Movement Disorders ®

“Recent advances in biochemical and imaging markers are opening novel perspectives for improving both the diagnosis, the definition, and the treatment of Parkinson’s disease. In this context, the PPMI study emerges as a global effort that holds great promise for a wide range of analyses.”

MILWAUKEE (PRWEB)
September 15, 2022

An alpha-synuclein seed amplification assay (SAA) showed positive detection results in prodromal cases of Parkinson’s disease according to a study released today at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

Development of tests to detect biomarkers for Parkinson’s disease (PD) are highly sought after to help with clinical care for potential PD patients. Biomarkers, such as alpha-synuclein, can aid in early diagnosis and risk assessment for PD development.

The Parkinson Progression Marker Initiative (PPMI) is a large observational study consisting of phenotyped PD patients, individuals at risk for developing PD, and healthy controls. Siderowf et al. sought to evaluate the efficiency of an alpha-synuclein SAA (developed by Amprion) on cerebral spinal fluid (CSF) samples from these groups of individuals. A total of 1,139 participants were included in this study. Sensitivity and specificity of the SAA was assessed and showed the highest accuracy in typical PD patients but was still found to show positive results in majority of prodromal cases.

Tiago Outeiro, Professor and Director of the Department of Experimental Neurodegeneration at the University Medical Center Göttingen, responded to this study, “recent advances in biochemical and imaging markers are opening novel perspectives for improving both the diagnosis, the definition, and the treatment of Parkinson’s disease. In this context, the PPMI study emerges as a global effort that holds great promise for a wide range of analyses. Using CSF samples from 1,139 cases, this research consortium assessed the value of an alpha-synuclein seed amplification assay (SAA) in a large cohort of patients with PD, individuals at-risk for PD and healthy controls. This is the major strength of this study, as previous efforts used a much smaller number of samples. The study confirmed the sensitivity and specificity of the SAA assay, as well as the ability to detect alpha-synuclein amplification in the CSF prodromal cases. Importantly, the study indicates that SAA will be an important tool to aid in the establishment of cohorts suitable for observational and interventional studies.”

View the full abstract text:

https://movementdisorders.org/2022-Congress-LBAs

Reference #: LBA-7

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email:

VPL presenting at specialty pharmacy’s premier event

“This event will really help us show the industry what we can do to help pharmacies simplify their prescription shipping workflows.”

COLUMBUS, Ohio (PRWEB)
September 15, 2022

This year’s National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo celebrates the 10-year anniversary of specialty pharmacy’s premier event, and VPL, an industry leader in smart supply chain solutions for healthcare clients, is continuing to support their expansion into the pharmacy market by exhibiting their cloud-based pharmacy solutions at the event. NASP 2022 will take place in Orlando, Florida at the Gaylord Palms Resort & Convention Center from September 19-22.

This past March, VPL announced the launch of their specialty pharmacy software solutions, VPL TrajectRx™—a clinically minded prescription shipping, tracking and compliance software built for pharmacists, by pharmacists to ensure specialty medications are delivered cost-effectively and securely.

“We’re excited to bring our pharmacy solutions to this year’s NASP Annual Meeting & Expo for the first time ever,” says Eric McGlade, CEO and Co-Founder at VPL. “Amanda Awe, our Pharmacy Product Specialist, spent over 10 years as a clinical pharmacist before coming to VPL to help other pharmacists solve familiar problems with technology solutions. Her unique perspective helps us to continuously innovate VPL TrajectRx, making it as useful to our customers as it can possibly be.”

VPL is proud to be leading two presentations for the Technology Day Workshop on Monday, September 19 in the mezzanine coastal breakout room Suwannee 1.

The first session, titled “Innovation Lab #5 – VPL & St. Luke’s,” is from 12:00-12:30 p.m. and will be presented by Marc Choquette (St. Luke’s), Derrek Seif (VPL), and Amanda Awe, PharmD, RPh (VPL). In this presentation, VPL will present a case study with a pharmacy customer that will demonstrate real world results of VPL TrajectRx.

The second session, titled “The Role of Technology in Solving ‘The Last Mile’ Logistics,” is from 4:30-5:30 p.m. and will be presented by Sheila Arquette, RPh (NASP), Amanda Awe, PharmD (VPL), Tim Ramsey (US Pack Logistics), Kirk Nilson (Parcel Shield). This panel will describe how specialty pharmacies use technology to provide customized, convenient, and customer-centric last-mile solutions to accommodate patients’ needs, improve customer satisfaction, manage costs, and safeguard medication quality.

“This event will really help us show the industry what we can do to help pharmacies simplify their prescription shipping workflows.” says McGlade. “I think those who sit in on her presentations will really enjoy them because they’ll be getting perspective on pharmacy software from an actual pharmacist who played a big role in the development of it all.”

Attendees can stop by the VPL TrajectRx booth (#606) to chat with their team about specialty pharmacies can make the prescription shipping workflow more seamless than ever before, find out what giveaway prizes they have available, and see what tricks their booth-side magician has up his sleeves.

About VPL

By making the procurement-through-fulfillment processes smarter and more profitable, VPL is creating a new supplier dynamic whereby customers benefit from reduced costs, better insights, and increased transparency and efficiency. The industry’s only Smart Supply Chain Platform automates inbound and outbound shipping, unlocks visibility into the status of critical shipments, and identifies cost-savings opportunities for all of healthcare including IDNs, critical access, outpatient, and pharmacy. With more than 700 hospitals pharmacies, and ambulatory surgery centers, 6,000+ suppliers, and a 97% customer retention rate, it’s clear that VPL is the company the healthcare industry trusts to deliver savings, insights, and peace of mind. To learn more or to schedule a demo, visit the company’s website at http://www.getvpl.com.

About NASP

NASP is a 501(c)(6) non-profit trade organization and is the only national association representing all stakeholders in the specialty pharmacy industry. The mission of the National Association of Specialty Pharmacy (NASP) is to elevate the practice of specialty pharmacy by developing, delivering, and promoting continuing professional education and specialty certification while advocating for public policies that ensure patients have appropriate access to specialty medications in tandem with critical services. NASP supports a free-market healthcare system in which all specialty pharmacies compete on the same fair and level playing field, because that is in the best interest of the patients we collectively serve. NASP is committed to working with all stakeholders and policymakers to ensure that all patients have access to the life-saving medications they need and the high touch patient care and support services they deserve from the pharmacy of their choosing. To learn more, visit http://www.naspnet.org.

Share article on social media or email:

We’re proud to be recognized by KLAS as being on the forefront of digital health software and services and giving patients the tools they’ve been asking for while demonstrating the positive impact on clinicians, as our industry forges a new path toward digital-first care delivery models.

CLEARWATER, Fla. (PRWEB)
September 15, 2022

DeliverHealth, a software and services company with a set of connected solutions that bridge the gap between mid-revenue cycle and digital health, announced today that its digital health platform has received high rankings in the 2022 KLAS Emerging Solutions Top 20 Report, including the top ranking in KLAS’s Improve Patient Experience category.

Built on its award-winning digital front door software and wrapped with a suite of omni-channel communication tools ranging from AI Virtual Assistant to Live Agent, the solution creates a one-of-a-kind user experience to enable Electronic Medical Record (EMR) functionality, scheduling, payment, telehealth visits, health risk assessments, patient monitoring, wayfinding, and more, in a single white-labeled, client-branded mobile application and web experience workflow.

The top 20 emerging solutions were selected by healthcare leaders across the country with the help of KLAS to find the solutions that have the greatest potential to disrupt the healthcare market. Solutions were rated by how well they could improve outcomes, reduce the cost of care, improve patient experiences, and improve clinician experiences, also known as the Quadruple Aim.

Notably, of the solutions considered by KLAS in relation to the Quadruple Aim, DeliverHealth ranked as the No. 1 solution for Improving Patient Experience, No. 4 for Improving Clinician Experience, tied at No. 6 for Improving Outcomes and tied at No. 9 for Reducing the Cost of Care — a testament to the company’s vision of simplifying the complexities in healthcare.

According to the report, one C-level executive noted being “very impressed” by DeliverHealth’s patient experience software, as “it wrapped functionality from several disparate solutions quite nicely, creating a seamless consumer experience.”

CEO of DeliverHealth Michael Clark said, “With 63% of patients now willing to leave their existing provider for one with a better digital experience, health systems have struggled to develop and execute holistic digital health strategies that unify the hundreds of available point solutions into a seamless consumer experience. DeliverHealth’s solutions integrator approach allows our clients to do just that, while our team of digital health consultants make sure our client’s people and processes are set up to drive adoption of their newly unified technologies. We’re proud to be recognized by KLAS as being on the forefront of digital health software and services and giving patients the tools they’ve been asking for while demonstrating the positive impact on clinicians, as our industry forges a new path toward digital-first care delivery models.”

The DeliverHealth Platform, with its mobile-focused capabilities, puts a clinical documentation and a coding ecosystem in the palms of a clinicians’ hands, providing quick access to transcription, scribing, translation services, coding audit workflows, and more. As the industry’s first true Digital Health Solutions Integrator, DeliverHealth incorporates into its digital front door omni-channel capabilities more than 30 point solutions and offers a team of adoption specialists to help customers create the healthcare ecosystem of the future, today. Earlier this year, those digital front door capabilities earned across-the-board A+ ratings from KLAS.

In KLAS’s Emerging Solutions Top 20 Report, another C-level executive mentioned that “any product [like DeliverHealth’s] that can bring together all the resources patients need into one platform is attractive to healthcare organizations trying to maintain a competitive edge.”

“Because KLAS believes in the power of technology to improve healthcare, it only made sense to research emerging, new solutions,” said Adam Gale, KLAS CEO. “We set out to help providers cut through the hype in this market and we found some new technologies with real capabilities. The recent Top 20 report highlights those solutions with the greatest potential impact according to healthcare leaders.”

To learn more about how DeliverHealth can help improve patient engagement and experience, visit http://www.deliverhealth.com.

About DeliverHealth

DeliverHealth is a healthcare software and services company with a set of connected solutions that bridge mid-revenue cycle and digital health together to improve the capabilities of health organizations to increase revenue, lower costs, demonstrate a return on investment, and create a healthier patient base. By building simplicity into our documentation, codification, and digital health patient experience platform, we make sure your people, processes, technology and patients are aligned and engaged for better outcomes and greater success. With clients and operations in five countries, and over three decades of Health Information Management expertise, DeliverHealth empowers today’s providers for the future of healthcare. Visit http://www.deliverhealth.com, or find us on LinkedIn, Twitter and Facebook.

About KLAS

KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights that provide early insights on the future of healthcare technology solutions. Follow KLAS on LinkedIn. Learn more at: klasresearch.com.

Share article on social media or email:

When asked why he chose the SightMD team, Dr. Russell said “The physicians and staff at SightMD are a team of dedicated, caring and compassionate experts placing the well being and needs of the individual above all else – which is consistent with my own philosophy and goals of patient care.”

HAUPPAUGE, N.Y. (PRWEB)
September 15, 2022

SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Scott Russell, MD to its expert team.

R. Scott Russell, MD is a comprehensive ophthalmologist who takes a genuine interest in researching and educating himself on various new advancements in ophthalmology, so his patients get the best and the most advanced treatment possible. He is driven to provide an excellent healthcare experience to all of his patients. Dr. Russell completed his undergraduate education at Boston College and Harvard College graduating with honors. He was awarded an N.I.H. Neurobiology Training Grant to study at the College of Physicians and Surgeons of Columbia University. After medical school he completed a general surgical internship at New York University, and his ophthalmology residency at Cornell. He also completed fellowships in Ophthalmic Pathology at the Armed Forces Institute of Pathology, and in Corneal, External Disease and Refractive Surgery at the L.S.U Eye Center. Dr. Russell served as a full time staff member in the Department of Ophthalmology of Columbia University and is an Assistant Clinical Professor in the department. His research interests include corneal pathology, and anterior segment surgery, about which he has published several papers and delivered several presentations. Dr. Russell will be seeing patients at SightMD locations in Riverhead (54 Commerce Dr Ste 6, Riverhead, NY 11901), Southold (41705 County Road 48, Southold, NY 11971), and Southampton (186 Old Town Road, Southampton, NY 11968).

When asked why he chose the SightMD team, Dr. Russell said “The physicians and staff at SightMD are a team of dedicated, caring and compassionate experts placing the well being and needs of the individual above all else – which is consistent with my own philosophy and goals of patient care.”

SightMD is actively seeking ophthalmology professionals who are interested in joining our outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact our VP of Growth, Franc Galinanes, at (631) 396-8340 or fgalinanes@sightgrowthpartners.com

About SightMD

SightMD is a rapidly-growing integrated ophthalmic provider group, offering patients access to over 80 eye care providers through the convenience of 40 locations across New York. SightMD’s track record of providing clinically-excellent care spans over 50 years, and its services include general eye exams, laser cataract surgery and lens implantation, glaucoma management, retinal disorder treatment, corneal services, neuro-ophthalmology, LASIK laser vision correction, oculoplastic surgery, pediatric ophthalmology, and audiology. Sight Growth Partners is the administrative services provider for SightMD. For more information about SightMD, please visit https://www.sightmd.com/sightmd-ny/

Share article on social media or email:

International Congress of Parkinson’s Disease and Movement Disorders ®

“This study is an important milestone in the development of continuous drug-delivery strategies to treat motor fluctuations in PD, showing significant increases in ON-time without troublesome dyskinesias using subcutaneous 24-hour infusions of a novel levodopa/carbidopa formulation.”

MILWAUKEE (PRWEB)
September 15, 2022

Continuous subcutaneous infusion (CSCI) of levodopa/carbidopa prodrugs, foslevodopa/foscarbidopa, improved time without dyskinesia in patients with advanced Parkinson’s disease (PD) according to a phase 3 clinical trial released today at the International Congress of Parkinson’s Disease and Movement Disorders® in Madrid, Spain.

It is well known that long-term use of oral levodopa/carbidopa leads to increased dyskinesia in PD patients. These motor symptoms are thought to be due to the rise and fall of dopamine. Therefore, many investigations have taken place to help treat and prevent the development of levodopa-induced dyskinesia.

The phase 3 clinical trial designed by Soileau et al. investigated the efficiency and safety of 24-hour CSCI foslevodopa/foscarbidopa, in patients with advanced PD. One hundred forty-one patients were randomized 1:1 to receive CSCI of foslevodopa/foscarbidopa and an oral placebo or CSCI of placebo and an oral dose of levodopa/carbidopa for 12 weeks. Treatment with CSCI of foslevodopa/foscarbidopa produced a greater improvement in time without dyskinesia when measured at week 12.

Werner Poewe, Professor of Neurology at the Medical University Innsbruck, Austria, responded to this study, “This study is an important milestone in the development of continuous drug-delivery strategies to treat motor fluctuations in PD showing significant increases in ON-time without troublesome dyskinesias using subcutaneous 24-hour infusions of a novel levodopa/carbidopa formulation. The observed effect size is similar to previous studies of levodopa/carbidopa intestinal gel infusions and results on secondary outcomes suggest benefits on sleep and early morning motor function. Local tolerability appears consistent with what is known from continuous subcutaneous apomorphine infusions in PD, suggesting that subcutaneous infusions of levodopa will soon be added to the portfolio of treatment options in PD patients with levodopa-related motor complications.”

View the full-text abstract:

http://www.mdsabstracts.org

Reference #: 775

*View all 6 of today’s breaking International Congress research news releases:

https://www.movementdisorders.org/MDS/News/Newsroom.htm

# # #

About the 2022 MDS International Congress of Parkinson’s Disease and Movement Disorders®:

The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson’s disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 1,500 original scientific abstracts and provide a forum for education and collaboration on latest research findings and state-of-the-art treatment options.

About the International Parkinson and Movement Disorder Society:

The International Parkinson and Movement Disorder Society (MDS), an international society of over 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit http://www.movementdisorders.org.

Share article on social media or email: